UroAlert - GU Oncology Weekly

July 10, 2025

Videos

Peer-to-Peer Clinical Conversations

Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis

Mark Tyson

Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting.

Evolution of Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata

Pedro Barata

Zachary Klaassen interviews Pedro Barata about the evolution of metastatic hormone-sensitive prostate cancer treatment.

Conference Coverage

SNMMI 2025: A Dose-Escalation Study of the Novel PSMA-Targeting Drug 177Lu-P17-088 in Patients with mCRPC

SNMMI 2025: 8-Year Follow-up of Patient Outcomes and Bone Health in Radium-223 Treated Patients: Data from the Global REASSURE Study

SNMMI 2025: Head-to-Head Comparison of mpMRI, PSMA, and GRPR PET/CT for Local Staging of Primary Prostate Cancer: Results from a Prospective, Single-Arm, Single-Center Multimodal Imaging Trial

Interdisciplinary GU Cancer Forum 2025: Novel Agents in NMIBC

Interdisciplinary GU Cancer Forum 2025: Artificial Intelligence in Molecular Targeted Imaging and Theranostics

Physician-Scientist Review Articles

Neoadjuvant Sintilimab with Gemcitabine and Cisplatin for Muscle-Invasive Bladder Cancer - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas of the urinary bladder.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Single-Cell RNA Sequencing Reveals Interaction Between Fibroblast Gene Signature and T-Cell Infiltration in Muscle-Invasive Bladder Cancer - Expert Commentary

Single-cell RNA sequencing reveals a fibroblast gene signature that promotes T-cell infiltration in muscle-invasive bladder cancer.

The current and future role of systemic therapy in non-muscle-invasive bladder cancer.

National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database.

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

BCAN Launches $1 Million Continuity Grant to Sustain Bladder Cancer Research

Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG Immunotherapy.

Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers.

Extracorporeal vs. intracorporeal urinary diversion at robot-assisted radical cystectomy: adverse in-hospital outcomes.

Health-related quality of life in patients treated for non-metastatic muscle-invasive bladder cancer: radical cystectomy versus bladder preserving therapy.

Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical Cystectomy.

Physical activity and risks of recurrence and progression among patients with non-muscle invasive bladder cancer.

Penile & Urethral Cancers

Clinicopathological features and reclassification of penile squamous cell carcinoma according to WHO classification 2022 for penile carcinoma with p16 immunohistochemical expression and its prognostic impact.

Prediction of distant metastases in penile squamous cell carcinoma: a SEER population-based study.

Renal Cancer

Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort.

Case Report: A rare pediatric case of B-cell lymphoblastic lymphoma presenting as an isolated renal mass with EWSR1::FLI1 translocation and germline CHEK2 variant.

Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).

Impact of RoSCo-based preoperative risk stratification on early mobilization and short-term outcomes following robot-assisted laparoscopic partial nephrectomy for renal cell carcinoma: a single-center prospective study.

Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

KIM-1 as a Prognostic Marker in Renal Cell Carcinoma.

Vigorous physical activity as a potential environmental risk factor in renal medullary carcinoma.

Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma.

Concordance between clinical and pathologic staging of larger (cT2a-b) and more invasive (cT3a) renal cell carcinoma.

Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Prostate Cancer

U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care

Human kallikrein 2: A novel lineage-specific surface target in prostate cancer.

AI lesion tracking in PET/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET/CT scans.

What's in a name? Why differentiation between biochemical recurrence and metastatic prostate cancer matters.

Cell-free DNA whole-genomes reveal chromosomal rearrangements associated with heterogeneity and stem cell-like castration-resistant prostate cancer.

Polygenic Risk Scores for Prostate Cancer: Comparative Evaluations in UK and Australian Cohorts.

Usefulness of free PSA ratio to enhance detection of clinically significant prostate cancer in patients with PI-RADS

Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.

Utilization, Acute Complications, and Delays in Treatment Associated with Rectal Spacers for Prostate Cancer Radiotherapy.

Patient-Reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer - Beyond the Abstract

Rectal spacer use and bowel, urinary, and sexual dysfunction diagnosis and related procedures among men receiving prostate radiotherapy: US county-level analysis.

Development and retrospective validation of an artificial intelligence system for diagnostic assessment of prostate biopsies: study protocol.

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.

External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System Aimed at Characterizing ISUP ≥ 2 Prostate Cancers at Multiparametric MRI.

Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy?

Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data.

Immunotherapy in metastatic prostate cancer.

The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era.

Generative Artificial Intelligence in Prostate Cancer Imaging.

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.

A Prospective Provincial Registry of 18F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.

Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.

Metformin-Associated Lactic Acidosis During Docetaxel Therapy for Castration-Resistant Prostate Cancer: A Case Report.

Online CBCT-based adaptive radiation with reduced PTV margins for prostate cancer: Does reference plan comparison tell the whole story?

Urethral and bladder dosimetry and urinary toxicity in prostate cancer patients undergoing SBRT with and without intra-prostatic boost.

Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.

Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers.

GLP-1 Agonist Use Among Men with Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials - Beyond the Abstract

PSMA MRI Guided Prostate SABR ARGOS-CLIMBER Phase I/II Trial: A Primary Endpoint Analysis - Beyond the Abstract

Comparative Adverse Event Profiles of Triplet Therapy Versus Docetaxel-Based Therapy in Patients with Metastatic Prostate Cancer: A Multicenter Retrospective Study - Beyond the Abstract

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study - Beyond the Abstract

Does the Surgeon's Learning Curve Impact Pentafecta Outcomes in Radical Prostatectomy? a Systematic Review and Meta-Analysis - Beyond the Abstract

The Added Value of Artificial Intelligence Using Quantib Prostate for the Detection of Prostate Cancer at Multiparametric Magnetic Resonance Imaging - Beyond the Abstract

Upper Tract Tumors

Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillance.

The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis.

Testicular Cancer

Near-complete resolution of tumour thrombus in a patient with advanced non-seminomatous germ cell tumour: a multidisciplinary approach without surgical intervention.

Mapping regional disparities in testicular cancer mortality across Spain (2004-2023).

Usefulness of apparent diffusion coefficient values and magnetic resonance imaging histogram analysis for identifying histological types of preoperative testicular tumors.

Interobserver reproducibility of hilar soft tissue invasion in testicular germ cell tumours among genitourinary pathologists.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC